GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of tried GIP for 23 weeks. here is what happened. — 20 comments in the full submission. View in context.
155
c/tirzepatide·submitted 2 months ago by u/spain_receta

tried GIP for 23 weeks. here is what happened.

Discussionbranch of 10 comments

Posting this as a discussion rather than a claim: tried GIP for 23 weeks. here is what happened. Numbers, in the order they matter: 23 weeks. The step schedule question, answered properly, because it comes up weekly. The label sets a minimum interval of four weeks between increases. That is a floor on how fast you…

Read the full submission and all 20 comments →

This branch

10 comments, started 2 months ago
u/ferran_mensah8 points·2 months ago

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/mikkel_kimani4 points·2 months ago

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme. They are different endpoints and the numbers do not transfer.

replysharereportpermalink
u/spain_recetaOP-21 points·2 months ago

Small fix: SURMOUNT is the obesity programme, SURPASS is the type-2 programme.

Saving this one. It is the clearest statement of the stall problem I have read here.

replysharereportpermalink
u/tarek_lokken1 point·2 months ago

hold the dose that works, the ladder is not a leaderboard

replysharereportpermalink
[removed]1 point·2 months ago

[removed by moderator]

replysharereportpermalink
u/forest_plot_fionastats3 points·2 months ago

Same experience with the appetite effect being flatter across the week rather than front-loaded.

replysharereportpermalink
u/elin_varga1 point·2 months ago

if 7.5 is working, 10 is not automatically better

replysharereportpermalink
u/zaid_balogun1 point·2 months ago

the appetite effect is blunter than sema, in a good way, most weeks

replysharereportpermalink
u/hugo_bergstrom1 point·2 months ago

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

replysharereportpermalink
u/spain_recetaOP1 point·2 months ago

Are you comparing yourself with the trial mean or with the people who post the most?

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.